Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

Mayo Clinic

Status and phase

Completed

Phase 4

Conditions

Obesity

Treatments

Other: Online support system

Drug: Placebo

Drug: Phentermine-Topiramate Extended Release

Study type

Interventional

Funder types

Other

Identifiers

NCT04408586

19-011697

Details and patient eligibility

About

Researchers are assessing the effects of weight loss medication vs a placebo among participants provided with a wearable activity tracker, digital wellness devices and lifestyle recommendations.

Enrollment

80 patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Adults with obesity (BMI >30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and controlled comorbidities or other diseases.
Age: 18-75 years.
Gender: Men or women. Women of childbearing potential will have negative pregnancy tests within 48 hours of enrollment.
Women of childbearing potential must agree to use a method of effective contraception during study participation.
Subject must have an Apple iPhone 6s or later with iOS 13 or later and be willing to download the VitalCare (VitalTech Affiliates LLC) application from the Apple App Store.
Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures

Exclusion Criteria

History of Abdominal bariatric surgery
Weight is greater than 450 lbs (204 kg)
Recent use (within the last three months) of any antiobesity medication
Recent weight change (gain or loss weight greater than 3% TBW in the last 3 months)
Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption, e.g., orlistat, within the last 6 months.
Significant untreated psychiatric dysfunction based upon screening with the Hospital Anxiety and Depression Inventory (HAD), and the Questionnaire on Eating and Weight Patterns (binge eating disorders and bulimia). If such a dysfunction is identified by an anxiety or depression score >11 or difficulties with substance or eating disorders, the participant will be excluded and given a referral letter to his/her primary care doctor for further appraisal and follow-up.
Hypersensitivity or contraindication to the study medication.
Participant unable or unwilling to follow protocol including use of the wearable activity tracker, digital wellness devices, VitalCare application, or unwilling to sign consent.
Principal Investigator discretion